These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32419601)

  • 21. [Expression of myeloid-derived suppressor cells in the peripheral blood and its clinical significance in renal carcinoma].
    Feng S; Liu C; Zheng S; Huang P; Chen B; Guo K
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):550-3. PubMed ID: 23644118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
    Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
    Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
    Vasquez-Dunddel D; Pan F; Zeng Q; Gorbounov M; Albesiano E; Fu J; Blosser RL; Tam AJ; Bruno T; Zhang H; Pardoll D; Kim Y
    J Clin Invest; 2013 Apr; 123(4):1580-9. PubMed ID: 23454751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition.
    Zhang ZN; Yi N; Zhang TW; Zhang LL; Wu X; Liu M; Fu YJ; He SJ; Jiang YJ; Ding HB; Chu ZX; Shang H
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):200-208. PubMed ID: 28570288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The number of myeloid-derived suppressor cells in the peripheral blood and tumor tissues in patients with gastric cancer and its clinical significance].
    Xia R; Wang F; Gao T; Wen W; Lu B; Zhu Y; Zhang X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):740-3. PubMed ID: 25001941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
    Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
    Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
    Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
    Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
    Verschoor CP; Johnstone J; Millar J; Dorrington MG; Habibagahi M; Lelic A; Loeb M; Bramson JL; Bowdish DM
    J Leukoc Biol; 2013 Apr; 93(4):633-7. PubMed ID: 23341539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1.
    Goh CC; Roggerson KM; Lee HC; Golden-Mason L; Rosen HR; Hahn YS
    J Immunol; 2016 Mar; 196(5):2283-92. PubMed ID: 26826241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
    Holderried TAW; de Vos L; Bawden EG; Vogt TJ; Dietrich J; Zarbl R; Bootz F; Kristiansen G; Brossart P; Landsberg J; Dietrich D
    Clin Epigenetics; 2019 Nov; 11(1):161. PubMed ID: 31747929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Δ9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8.
    Sido JM; Yang X; Nagarkatti PS; Nagarkatti M
    J Leukoc Biol; 2015 Apr; 97(4):677-88. PubMed ID: 25713087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The roles of polymorphonuclear myeloid-derived suppressor cells in endometriosis.
    Satake E; Koga K; Takamura M; Izumi G; Elsherbini M; Taguchi A; Makabe T; Takeuchi A; Harada M; Hirata T; Hirota Y; Wada-Hiraike O; Osuga Y
    J Reprod Immunol; 2021 Nov; 148():103371. PubMed ID: 34517223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
    Huang H; Zhang G; Li G; Ma H; Zhang X
    Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.
    Salem ML; Zidan AA; Attia M; El-Naggar RE; Nassef M; Abou El-Azm AR; El-Bate H; Yussif M; Galal S; Abo Senna M; El Demellawy M
    Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):188-198. PubMed ID: 28472907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery.
    Wang J; Su X; Yang L; Qiao F; Fang Y; Yu L; Yang Q; Wang Y; Yin Y; Chen R; Hong Z
    Int J Cancer; 2016 Jun; 138(11):2688-99. PubMed ID: 26756887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid-Derived Suppressor Cells Show Different Frequencies in Diabetics and Subjects with Arterial Hypertension.
    Fernández-Ruiz JC; Galindo-De Ávila JC; Martínez-Fierro ML; Garza-Veloz I; Cervantes-Villagrana AR; Valtierra-Alvarado MA; Serrano CJ; García-Hernández MH; Enciso-Moreno JA; Castañeda-Delgado JE
    J Diabetes Res; 2019; 2019():1568457. PubMed ID: 31915708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
    Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
    Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.